These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 26071896)
1. Balancing Risks in Developing a Personalised Approach to the Treatment of Early Hodgkin Lymphoma: A Haematologist's Perspective. Follows GA Clin Oncol (R Coll Radiol); 2015 Aug; 27(8):457-9. PubMed ID: 26071896 [No Abstract] [Full Text] [Related]
2. Balancing Risks in Developing a Personalised Approach to the Treatment of Early Hodgkin Lymphoma: Have We Got the Balance Right? Illidge T Clin Oncol (R Coll Radiol); 2015 Aug; 27(8):454-6. PubMed ID: 26108883 [No Abstract] [Full Text] [Related]
4. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V; J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100 [TBL] [Abstract][Full Text] [Related]
5. Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease. Busia A; Laffranchi A; Viviani S; Bonfante V; Villani F Anticancer Res; 2010 Oct; 30(10):4381-7. PubMed ID: 21036768 [TBL] [Abstract][Full Text] [Related]
6. [Acute non-lymphatic leukemia after treatment of Hodgkin's lymphoma with chemotherapy and radiotherapy]. Lira P; Grebe G Rev Med Chil; 1984 Oct; 112(10):1021-5. PubMed ID: 6085597 [No Abstract] [Full Text] [Related]
7. [Chemotherapy of malignant lymphomas]. Luporini G Radiol Med; 1976; 62(7-8):553-7. PubMed ID: 95671 [TBL] [Abstract][Full Text] [Related]
8. [Role of response to first-line chemotherapy and of the primary lesion in Hodgkin lymphoma]. Datsenko PV; Pan'shin GA; Sotnikov VM; Ivashin AV; Gombolevskiĭ VA; Golub SV; Evstikheev ÉV Vopr Onkol; 2012; 58(1):66-70. PubMed ID: 22629831 [TBL] [Abstract][Full Text] [Related]
9. [Results of the treatment of lymphogranulomatosis]. Kholin AV Ter Arkh; 1986; 58(2):143-7. PubMed ID: 2422774 [No Abstract] [Full Text] [Related]
10. Treatment of advanced stage Hodgkin lymphoma--it's all about risk-benefit. Phipps C; Lee YS; Hwang W Br J Haematol; 2012 Oct; 159(1):113-5. PubMed ID: 22823109 [No Abstract] [Full Text] [Related]
11. [Hodgkin's lymphoma and radiotherapy]. Datsenko PV; Panshin GA Vopr Onkol; 2015; 61(1):45-51. PubMed ID: 26016145 [TBL] [Abstract][Full Text] [Related]
12. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group. Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455 [TBL] [Abstract][Full Text] [Related]
13. [The optimal total focal radiotherapy dosage after first-line chemotherapy in patients with Hodgkin lymphoma]. Datsenko PV; Pan'shin GA; Sotnikov VM; Ivashin AV; Evstikheev ÉV; Golub SV; Gombolevskiĭ VA Vopr Onkol; 2012; 58(4):527-31. PubMed ID: 23607209 [TBL] [Abstract][Full Text] [Related]
14. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848 [TBL] [Abstract][Full Text] [Related]
15. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592 [TBL] [Abstract][Full Text] [Related]
16. [Advances in the chemotherapy of malignant lymphoma 1. Chemotherapy of Hodgkin's disease]. Suon SZ Zhonghua Nei Ke Za Zhi; 1985 Feb; 24(2):117-120, contd. PubMed ID: 2580675 [No Abstract] [Full Text] [Related]
17. Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy? Diehl V; Engert A Nat Clin Pract Oncol; 2006 May; 3(5):227. PubMed ID: 16682982 [No Abstract] [Full Text] [Related]
18. [Results of the treatment of Hodgkin's disease stage III and IV using the ABVD and BACOP programs]. Leszko B; Słomkowski M; Przybyszewska M; Apel D; Pawelski S Acta Haematol Pol; 1986; 17(3-4):81-90. PubMed ID: 2438894 [No Abstract] [Full Text] [Related]
19. [Controversy regarding the treatment of Hodgkin's disease]. Balwierz W; Armata J Pol Tyg Lek; 1989 Apr; 44(14):315-9. PubMed ID: 2482966 [No Abstract] [Full Text] [Related]
20. Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation. Sénécal D; Jais JP; Desablens B; Berthou C; Casassus P; Moles MP; Delwail V; Gastinne T; Colonna P; Andrieu JM Cancer; 2008 Feb; 112(4):846-55. PubMed ID: 18072259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]